Latest Regulatory Engagement News

Locksley Resources has launched an Expression of Interest process to select a leading U.S. engineering firm for the Desert Antimony Mine pilot plant design, marking a critical step toward establishing a domestic antimony supply chain aligned with federal priorities.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Dateline Resources reaffirms the robustness of its Colosseum Gold-REE Project while denying legal claims over rare earth tenements, signaling confidence in its growth strategy.

Viridis Mining and Minerals has secured a favorable technical assessment for its Colossus Project's environmental license, setting the stage for a critical council review in December.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

Ardea Resources updates its Definitive Feasibility Study for the Kalgoorlie Nickel Project, confirming a streamlined processing approach and a new sale product that could enhance project economics and market reach.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Kingsgate Consolidated Limited reported record quarterly gold and silver production at its Chatree Gold Mine, alongside strong cash growth and strategic project advances in its November 2025 AGM update.

Raiden Resources has acquired an 85% commercial interest in the Crixás Gold Tailings Project in Brazil, aiming to unlock near-term, low-capital gold production through tailings reprocessing. The project features existing infrastructure and a third-party processing plant, with a feasibility study underway for a larger gravity processing facility.

TPG Telecom has disclosed a fatal incident linked to outdated Samsung device software blocking emergency Triple Zero calls, while progressing a major capital raising.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

MyEco Group reveals a strategic pivot towards expanding its MyEco branded products, achieving a 9% sales increase in FY25, and implementing a $2.5 million cost-saving operational restructure aimed at EBITDA breakeven in FY26.